{"name":"Gunkang Pharmaceuticals, Inc","slug":"gunkang-pharmaceuticals-inc","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Metabolic","slug":"metabolic","revenue":0,"percentOfTotal":0,"drugCount":3,"colorKey":"oncology","drugs":[{"name":"GNS-212-E1","genericName":"GNS-212-E1","slug":"gns-212-e1","indication":"Type 2 diabetes","status":"phase_3"},{"name":"GNS-212-ER","genericName":"GNS-212-ER","slug":"gns-212-er","indication":"Type 2 diabetes","status":"phase_3"},{"name":"GNS-212-E2","genericName":"GNS-212-E2","slug":"gns-212-e2","indication":"Type 2 diabetes","status":"phase_3"}]}],"pipeline":[{"name":"GNS-212-E1","genericName":"GNS-212-E1","slug":"gns-212-e1","phase":"phase_3","mechanism":"GNS-212-E1 is a small molecule that targets the SGLT2 receptor.","indications":["Type 2 diabetes"],"catalyst":""},{"name":"GNS-212-ER","genericName":"GNS-212-ER","slug":"gns-212-er","phase":"phase_3","mechanism":"GNS-212-ER is a small molecule that targets the SGLT2 receptor.","indications":["Type 2 diabetes"],"catalyst":""},{"name":"GNS-212-E2","genericName":"GNS-212-E2","slug":"gns-212-e2","phase":"phase_3","mechanism":"GNS-212-E2 is a small molecule that targets the SGLT2 receptor.","indications":["Type 2 diabetes"],"catalyst":""}],"recentEvents":[],"realNews":[],"patents":[],"drugCount":3,"phaseCounts":{"phase_3":3},"enrichmentLevel":2,"visitCount":1,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}